Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Arizona Tribune - Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 21,236,346 to approximately 2,123,635.

Text size:

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

E.Hall--AT

RBGPF	-0.45%	60.34	$
CMSD	-0.95%	22.08	$
BTI	-0.02%	58.9	$
GSK	0.14%	50.74	$
NGG	1.89%	80.97	$
BCE	-2.78%	22.65	$
AZN	0.85%	176.43	$
CMSC	-0.95%	22.16	$
BP	1.71%	39.78	$
RIO	-0.72%	99.36	$
RELX	-1.14%	30.83	$
RYCEF	1.23%	18.63	$
JRI	-0.16%	12.65	$
BCC	-2.92%	72.54	$
VOD	-1.27%	14.12	$

Arizona Tribune - Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Featured

Kenya police violence victims say compensation promise a 'smokescreen'

North America LiberNovo Prime Sale Fully Launches June 23

InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 23

Who Is Really Influencing Trump Marijuana Rescheduling?